微泡增强经颅聚焦超声联合替莫唑胺治疗高级别胶质瘤:BT008NA多中心开放标签1/2期试验
BT008NA是一项在美国和加拿大5个中心开展的多中心、开放标签、单臂1/2期试验,评估微泡增强经颅聚焦超声(MB-FUS)打开血脑屏障联合标准替莫唑胺化疗治疗新诊断高级别胶质瘤的安全性和可行性。
要点
- MB-FUS联合替莫唑胺在高级别胶质瘤中安全可行,所有治疗均可见血脑屏障开放。
- MB-FUS相关不良事件多为1-2级,无治疗相关死亡。
核心结论
- MB-FUS联合替莫唑胺是高级别胶质瘤的安全联合治疗策略,可能改善生存并实现基于血浆生物标志物的无创疾病监测,值得开展随机对照试验。
研究设计与样本
- BT008NA为开放标签、单臂、1/2期试验,在美国和加拿大5个中心开展。
- 纳入34例新诊断高级别胶质瘤(WHO 2016标准胶质母细胞瘤)患者,年龄18-80岁,KPS≥70,接受最大安全切除和6周放化疗后准备开始标准替莫唑胺辅助化疗(150 mg/m2体表面积)。
- MRI引导的220 kHz经颅MB-FUS于28天替莫唑胺周期的前3天中任一天给予,最多6个周期,治疗区域为切除周边(肿瘤浸润)区。
- 主要终点为安全性(不良事件)和可行性(血脑屏障开放:术后T1加权MRI新发对比增强),预设次要终点为总生存期和无进展生存期,采用意向性治疗人群分析。
主要发现
- 共记录176例不良事件:54例(31%)化疗相关,10例(6%)疾病相关,87例(49%)与MB-FUS相关(40例[46%]为1级,46例[53%]为2级,1例[1%]为3级),25例(14%)无关。
- 2例(1%)不良事件为5级(疾病相关死亡),3例(2%)为4级(替莫唑胺相关血液学异常),8例(5%)为3级(3例[2%]替莫唑胺相关,1例[1%]MB-FUS相关,3例[2%]疾病相关,1例[1%]无关);这些事件发生于34例中的7例(21%)。
- 试验期间无治疗相关死亡,所有治疗均可见血脑屏障开放。
临床怎么用
- 对于新诊断高级别胶质瘤患者,在标准替莫唑胺辅助化疗期间可考虑联合MB-FUS打开血脑屏障以促进局部药物递送。
- MB-FUS相关不良事件以1-2级为主,但需监测3级及以上事件,整体安全性可接受。
- MB-FUS富集血浆游离DNA轨迹与疾病进程一致,提示sono-liquid biopsy可作为无创疾病监测的潜在工具。
局限性
- 本研究为单臂设计,无随机对照,样本量较小(34例),结论需随机对照试验验证。
- 研究纳入人群以白人(82%)和非西班牙裔(100%)为主,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brain-infiltrating tumour cells from high-grade glioma remain shielded from drug treatments by the blood-brain barrier, leading to inevitable recurrence. Microbubble-enhanced transcranial focused ultrasound (MB-FUS) enables controlled blood-brain barrier opening (BBBO), permitting localised drug delivery. We aimed to assess safety and feasibility of MB-FUS plus standard-of-care chemotherapy for individuals with high-grade glioma. METHODS: BT008NA was an open-label, single-arm, phase 1/2 trial conducted at five sites in the USA and Canada (part of the ReFOCUSED Consortium). Key eligibility criteria were participants with newly diagnosed high-grade glioma (glioblastoma as per WHO 2016 classification), aged 18-80 years, with normal organ function, a baseline Karnofsky Performance Status score of 70 or higher, who had received maximal safe resection and 6-week chemoradiotherapy and were to start standard-of-care monthly adjuvant temozolomide chemotherapy (150 mg/m2 of body surface area). MRI-guided, 220 kHz transcranial MB-FUS treatments were delivered in periresectional (tumour-infiltrative) regions, on any of the first 3 days of a 28-day temozolomide cycle, for up to six cycles. Primary outcomes were safety (adverse events) and feasibility (BBBO: new contrast enhancement on post-procedure T1-weighted MRI). Protocol-prespecified secondary outcomes were overall survival and progression-free survival. Analyses were done in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT03551249 (USA) and NCT03616860 (Canada), and is closed to enrolment. FINDINGS: Between Oct 16, 2018, and March 9, 2022, we enrolled 34 participants, all evaluable for prespecified primary and secondary endpoints, with a mean age of 51·5 years (SD 13·0) and median follow-up 44·5 months (95% CI 34·9-57·3). By self-reporting, 18 (53%) participants were female and 16 (47%) male, 28 (82%) were White, and 34 (100%) were non-Hispanic. 176 adverse events were captured: 54 (31%) chemotherapy-related, 10 (6%) disease-related, 87 (49%) related to undergoing MB-FUS (40 [46%] grade 1, 46 [53%] grade 2, and one [1%] grade 3), and 25 (14%) unrelated. Two (1%) of the adverse events were grade 5 (disease-related deaths), three (2%) grade 4 (temozolomide-related haematological abnormalities), and eight (5%) grade 3 (three [2%] temozolomide-related, one [1%] MB-FUS-related, three [2%] disease-related, and one [1%] unrelated); these occurred across seven (21%) of 34 participants. No treatment-related deaths occurred during the trial. BBBO was visualised in all treatments. Median overall survival was 31·3 months (95% CI 21·1-not reached) and median progression-free survival was 13·5 months (9·9-26·9) with patient-specific disease courses found concordant with trajectories of MB-FUS-enriched plasma cell-free DNA. INTERPRETATION: MB-FUS plus temozolomide is a safe combinatorial therapeutic approach for individuals with high-grade glioma, with the potential to improve survival and enable non-invasive plasma biomarker-based disease surveillance (sono-liquid biopsy), warranting randomised controlled trials. FUNDING: National Institutes of Health and Insightec.
引用
- Woodworth GF, Anastasiadis P, Ozair A, et al. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2025. PMID: 41308679. doi:10.1016/S1470-2045(25)00492-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。